CDMO Kindeva Drug Delivery has announced an expansion at its facility in Loughborough, UK to add dedicated laboratory space for analytical laboratory services. According to the company, the new Loughborough facility will double its lab space in the UK. In January 2024, Kindeva announced that it was launching an analytical laboratory services business and was opening a 32,000 sq ft lab in Minnesota to house that group.
In addition to the analytical services space, the company says that the facility may house development and other “future innovation and sustainability opportunities” in the future. Kindeva recently announced that it will add a second MDI manufacturing line for inhalers using LGWP propellants and says that the laboratory expansion is intended to support commercialization of LGWP inhalers.
The Loughborough facility’s VP of Manufacturing and Operations, Carl Brookes, commented, “As Kindeva continues to grow worldwide, this expansion is one more step in furthering the commercialization of our customers’ low GWP pMDI products. This is an exciting time for green propellants, and Kindeva is committed to remaining at the forefront of these product transitions supporting a greener planet. As Kindeva continues to develop more sustainable technologies and processes, we are constantly evaluating the potential across all our drug-device platforms and our sites. Our expansion on Charnwood Campus will help Kindeva continue to advance with leading facilities for our employees who are tasked with ensuring some of the highest standards of quality and safety for the products we make, and ultimately improving the health of patients we serve.”
Read the Kindeva Drug Delivery press release.
